asset

News

Noxxea Wins the Scientific Committee Prize at Encéphale congress - January 2025

We are honored to receive the Scientific Committee Prize at the
2025 Encéphale Congress. This recognition highlights key milestones for our unique model of digital medicines, fully dedicated to sleep disorders. After several years of development, our solution, Noxxea, has emerged as the first 100% digital and personalized treatment for insomnia, based on the principles of Cognitive Behavioral
Therapy (CBT).

Di&Care and Noxxea at the Encéphale Congress - January 2025

In January 2025, Di&Care and Noxxea participated in the prestigious Encéphale Congress, a leading event in the field of mental health and psychiatry.

Meeting of the Di&Care Scientific Committee - January 2025

As every year, Di&Care brought together its scientific committee, composed of sleep specialists, psychiatrists, and generalpractitioners. This enriching day of discussions aims to advance our programs, with the constant goal of offering innovative and personalized solutions for patients.

Di&Care, Winner of the CIC Business Award

In December 2024, Di&Care was honored at the CIC Business Award in Lille for its model of digital medicines in mental health, marking a significant milestone in the development of our company.

Noxxea showcased at the SFMRS - November 2024

Noxxea made its first appearance at the French Society of Sleep Medicine, marking a crucial milestone in increasing its visibility. Noxxea is the first 100% digital and French treatment for insomnia.

Pépite Award Hodéfi - September 2024

Di&Care was honored with the Pépite Award, a distinction that supports innovative and creative business creation projects. Hodéfi, founded in 1983 by the Grand Lille Chamber of Commerce and Industry, has been supporting businesses for over 30 years, specializing in innovation.